Companion Animal Vaccine Market Analysis & Forecast: 2025-2032

Companion Animal Vaccine Market Size and Trends 2025- 2032

The Companion Animal Vaccine Market is estimated to be valued at USD 3.82 Bn in 2025 and is expected to reach USD 6.05 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Key Takeaways

• Based on Product type, the Attenuated Live Vaccine is expected to hold a dominant position in the global companion animal vaccine market during the forecast period, and this is attributed to increasing product approvals and launches during the forecast period.
• Based on Species type, Feline is expected to dominate the market over the forecast period, accounting for 36.2% of the market share, attributed to the increasing adoption of cats as common pets around the world.
• Based on Distribution Channel, the Veterinary Clinics are expected to dominate the market over the forecast period, and this is attributed to the prompt vaccination by hospitals.
• Based on Region, the North America region is expected to dominate the market holding around 48.3% of the market share, and this is attributed to the increasing heathcare funding by government.

Market Overview

The Companion Animal Vaccine market is an emerging market that focuses on the manufacturing of vaccines that can be effective in protecting domesticated animals, primarily pets like cats and dogs, from diseases like rabies. It is rapidly growing, owing to a rise in pet ownership, awareness regarding pet health, and the surge in diseases like rabies, distemper, etc.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Reimbursement Scenario in Companion Animal Vaccine Market

Pet insurance companies have started covering core vaccines for dogs and cats, such as rabies, parvovirus, and distemper, particularly under wellness plans or preventive care add-ons. The coverage typically includes the cost of the vaccine itself, as well as the office visit fee. Trupanion, one of the largest pet insurers in North America, offers reimbursement for vaccines as part of their wellness packages. Pets Best provides a Preventative Care Add-On which covers vaccines as part of a broader wellness plan, including dental cleanings and flea treatments. The ASPCA has also contributed to vaccine reimbursement programs by offering low-cost or free vaccines through clinics in underserved areas. Pop-up vaccination clinics are becoming a more common model, and reimbursement for these services may be covered by either government grants or non-profit funding sources to offset veterinary costs.

As of February 2025, a total of 110.49 crore doses have been administered for FMD, 4.57 crore doses for Brucellosis, 25.36 crore doses for PPR, and 0.70 crore doses for CSF in India.

Segmental Insights

To learn more about this report, Request sample copy

Companion Animal Vaccine Market Insights, by Species Type

Rise in Cat Ownership is Driving the Feline Segment’s Growth

Based on the Species Type, the Feline segment is dominating the market, accounting for around 36.2% of the global market share. The growth of this segment is attributed to the increasing cat ownership across the globe. The Feline category among animals is said to be susceptible to many infections and diseases. This increases the need to get them vaccinated from time to time. For instance, according to a study conducted by Simon F. Haeder, Associate Professor of Public Health, Texas A&M University, in 2024, there are around 4% of dogs and 12% of cats remain unvaccinated against rabies. Around 22% of dog owners and 26% of cat owners are hesitant to get their pets vaccinated. This further propels the companion animal vaccine maret demand.

Companion Animal Vaccines Market Insights, by Product Type

Cost-effectiveness is Driving the Attenuated Live Vaccine Segment’s Growth

On the basis of Product Type, the Attenuated Live Vaccine segment is expected to lead the market in 2025. These vaccines are known for their ability to induce long-lasting immunity. It comprises weakened pathogens that replicate without causing any disease. It is not only cost-effective but is also efficient and is widely adopted in veterinary practices.

In August 2024, Texas-based Low Cost Pet Vax launched its first pop-up vaccination clinics in Miami, Florida. These walk-in clinics, operating on weekends at local business parking lots, offer veterinary-supervised services.

Companion Animal Vaccines, by Distribution Channel

Vaccination Compliance is Driving the Veterinary Clinics Segment’s Growth

Based on the Distribution Channel, the Veterinary Clinics segment is leading the market. Veterinary clinics act as the first point of contact for pet owners seeking preventive care. Many services are offered by these clinics, such as personalized care, follow-up services, etc., which drive the vaccination compliance. Additionally, there are also collaborations between veterinary clinics and vaccine manufacturers that help in ensuring the availability of vaccines easily and at all times. However, post-pandemic, the consumer behaviour has changed, with rising costs, etc., having taken a toll on the business sustainability. In September 2024, the ASPCA opened its third Community Veterinary Clinic. The clinic aims to provide affordable veterinary care to thousands of pets in underserved areas, improving the health and well-being of local dogs and cats.

Regional Insights

To learn more about this report, Request sample copy

North America Companion Animal Vaccines Market Trends

Among regions, North America is estimated to hold a dominant position in the global companion animal vaccine market over the forecast period. North America is estimated to hold 48.3% of the market share in 2025. The global companion animal vaccine market is expected to witness significant growth in the coming years, driven by the high prevalence of orthopedic disorders and dysfunctions, favorable health reimbursement, and increased awareness. The increasing prevalence of neurological disorders is contributing to the growth of the companion animal vaccine market in the North America region.

The U.S. and Canada are the top two countries contributing significantly to the growth of the Companion Animal Vaccine Market of the region. The U.S. is leading the region, owing to its increased efforts in Research & Development. In February 2024, the University of Pennsylvania School of Veterinary Medicine (Penn Vet) launched its mRNA Research Initiative to accelerate the development of veterinary mRNA vaccines and host-directed therapies. The new product launches and approvals of vaccines are expected to increase the number of vaccines produced in the U.S., thereby driving demand for veterinary services in the U.S. Meanwhile, Canada also follows the same trends of pet adoption, and along with it an increase in demand for advanced veterinary vaccines, also drives the market’s growth in Canada.

Europe Companion Animal Vaccines Market Trends

Europe is the second-largest market. The growth here can be attributed to a variety of different factors, such as widespread pet ownership, a well-established veterinary healthcare infrastructure. The focus of the market in this region is on preventive care, which is also backed by a few government initiatives and pet welfare organizations. Moreover, the presence of several leading pharmaceutical companies also helps the market grow. The two countries that play a pivotal role in shaping the market include Germany and the U.K. Germany is dominating the market in this region due to its large pet population and considerable investment in animal welfare. However, the U.K., too, has a very well-established pet healthcare system, which significantly contributes to the companion animal vaccine market growth.

In November 2024, Ceva Animal Health announced its investment in European vaccine manufacturing with the construction of a new facility in Hungary, boosting the capacity of Ceva Phylaxia.

Companion Animal Vaccine Market Trends

Introduction of companion animal vaccines with advanced technology.

Introduction of companion animal vaccine with advanced technology in the market is expected to drive the growth of the global companion animal vaccine market over the forecast period. The integration of advanced technologies such as recombinant DNA, mRNA, etc. is leading the market to a new era with lots of innovations on the way. These innovations are expected to improve the efficiency of vaccines, extend the duration of immunity, and reduce side effects. The rise in pet ownership is also significantly contributing to the increase in demand for vaccines, which in turn leads to the development of new and efficient technologies. For instance, in November 2021, Stryker Corporation, a multinational medical technology corporation based in the U.S., launched the Prophecy Infinity Resect-Through Guides for use in total ankle replacement surgeries. The system represents the refinement of Stryker’s industry gold standard technique, allowing surgeons to improve efficiency by reducing potentially time-consuming interoperative steps in a streamlined surgical process.

Companion Animal Vaccine Market Opportunities

Increased Strategic Partnership and Collaboration for Production of Novel Veterinary Vaccine

Key market players are focusing on strategies such as partnership and collaboration to increase production and innovation in companion animal vaccines, which is providing opportunities for new vaccine launches, which is expected to drive demand during the forecast period. For instance, in March 2023, the Biotechnology and Biological Sciences Research Council (BBSRC), a part of UK Research and Innovation (UKRI), and the Bill & Melinda Gates Foundation, a U.S.-based private foundation, announced the creation of a new center at The Pirbright Institute to accelerate the development of animal vaccines to combat emerging and urgent infectious diseases.

Companion Animal Vaccine Market Drivers

Increasing zoonotic diseases cause Public Health Threats

There are several advantages to having a companion animal. Pet popularity of stroking cats and dogs is expanding globally, however, pets can occasionally carry hazardous germs that can be transmitted to people and cause sickness. These are known as zoonotic illnesses. As per data for zoonotic diseases in Eastern Europe published in July 2020 by the World Health Organization (WHO), it is estimated that globally, about one billion cases of illness and millions of deaths occur every year from zoonoses. Over 30 new human pathogens have been detected in the last three decades, 75% of which have originated in animals.

Market Report Scope

Companion Animal Vaccine Market Report Coverage

Companion Animal Vaccine Market - Cross-Sectional Analysis

Among product types, the Attenuated Live Vaccine segment is dominant during the forecast period in the North America region due to the key players focusing on organic strategies such as the launch of new products, which is expected to drive segment growth over the forecast period. For instance, on June 12, 2023, MSD Animal Health announced approval of INNOVAX-ILT-IBD from the U.S. Food and Drug Administration and the European Commission for the Innovax vaccine, a dual-construct HVT vaccine that provides long-term protection against infectious laryngotracheitis. Such predicted approvals and launches are fueling the global companion animal vaccines market in North America.

Key Developments

• In May 2025, Andhra Pradesh Chief Minister N. Chandrababu Naidu introduced Biolumpivaxin, a vaccine developed by Biovet, designed to enhance disease surveillance in livestock and protect them from lumpy skin disease (LSD).
• In February 2025, the Bruhat Bengaluru Mahanagara Palike launched a combined vaccine scheme for street dogs.
• In November 2024, Boehringer Ingelheim launched the EURICAN® L4 vaccine to protect dogs from leptospirosis. Initially available in France, it will expand to other European countries in 2025.
• In September 2022, Merck Animal Health announced the donation of five million doses of its NOBIVAC rabies vaccine to help eliminate canine-mediated rabies through the Afya program. Mission Rabies has now vaccinated nearly two million dogs through Merck Animal Health’s Afya program.

Analyst Viewpoint

• The companion animal vaccine market is on the cusp of a technological revolution. mRNA vaccines, previously a concept relegated to human medicine, are quickly finding a place in veterinary applications. The launch of Boehringer Ingelheim’s EURICAN® L4 vaccine for leptospirosis is a prime example of how the industry is beginning to incorporate cutting-edge technology to offer better, longer-lasting protection. As veterinary professionals become more attuned to the value of targeted, precise solutions, expect a surge in demand for vaccines that provide broader immunity with fewer side effects. The University of Pennsylvania’s mRNA Research Initiative for veterinary vaccines is another harbinger of this trend. This move could redefine how we approach zoonotic diseases and chronic conditions in pets.
• Regulatory frameworks around animal health are tightening. The introduction of new vaccines, especially ones utilizing mRNA technology, will undoubtedly face greater scrutiny. In particular, the U.S. FDA’s Center for Veterinary Medicine (CVM) has been increasing its focus on the approval and monitoring of veterinary vaccines. The demand for stringent efficacy and safety trials could slow down the pace at which innovative vaccines enter the market. However, those that succeed in navigating this regulatory maze will command premium market positions. Smaller biotech companies focusing on niche diseases may find themselves acquired by larger players, as we’ve seen with Ceva Animal Health’s recent expansion into European vaccine manufacturing, through their investment in Ceva Phylaxia in Hungary.

Market Segmentation

• Global Companion Animal Vaccine Market, By Product Type
  • Attenuated Live Vaccine
  • Conjugate Vaccine
  • Inactivated Vaccine
  • Subunit Vaccine
  • Toxoid Vaccine
  • DNA Vaccine
  • Recombinant Vaccine
• Global Companion Animal Vaccine Market, By Animal Type
  • Canine
  • Feline
  • Equine
  • Others
• Global Companion Animal Vaccine Market, By Distribution Channel
  • Veterinary Clinics
  • Veterinary Hospitals
  • Veterinary Research Institute
  • Others
• Global Companion Animal Vaccine Market, By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Company Profiles
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim GmbH
  • Ceva Ltd.
  • Merck & Co. Inc.
  • Virbac
  • Zoetis Inc.
  • HIPRA
  • Biogénesis Bago
  • Ourofino Animal Health
  • Croda International Plc
  • KM Biologics
  • Indian Immunological Ltd.
  • Sinovac
  • Kyoto Biken vLaboratories, Inc.
  • HESTER BIOSCIENCES LIMITED
  • Calier
  • Bioveta

Sources

Primary Research Interviews

• In-depth interviews with veterinarians, industry experts, distributors, regulatory authorities, and key stakeholders in the animal health sector.

Databases

• Government health and veterinary databases
• International trade and customs databases
• Animal health regulatory portals (e.g., USDA, EMA)

Magazines

• Veterinary Practice News
• Animal Wellness Magazine
• Pet Product News International

Journals

• Journal of Veterinary Science
• Vaccine
• Veterinary Microbiology
• Journal of the American Veterinary Medical Association (JAVMA)

Newspapers

• The New York Times (Health and Science sections)
• The Guardian (Science and Environment)
• Business Standard (Healthcare industry news)

Associations

• American Veterinary Medical Association (AVMA)
• World Small Animal Veterinary Association (WSAVA)
• International Alliance for Biological Standardization (IABS)
• Federation of Veterinarians of Europe (FVE)

Public Domain Sources

• World Organisation for Animal Health (WOAH)
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Published government and NGO reports
• Open-access research repositories

*Definition: Companion animal vaccinations are those administered to pets (such as dogs and cats) to stimulate their immune responses. Companion animal vaccines, in other words, are used to improve the functioning of the immune system in pets and other animals.